ClinicalTrials.gg
Not yet recruitingNCT07110662NET-CD38Updated Aug 7, 2025

New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.

A Phase 1/2 interventional study of DARATUMUMAB (DARZALEX®) in Toxic Epidermal Necrolysis, Immunotherapy and Cutaneous Adverse Drug Reactions (CADR), sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Hospices Civils de Lyon · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Toxic Epidermal Necrolysis (TEN) are rare diseases that are dermatologic emergencies characterized by widespread epidermal necrosis and sloughing of skin. A hundred patients are affected each year in France. The main symptom is bullous and skin detachment > 10% which gradually progresses to extensive necrosis of the 100% BSA epidermis. The mortality rate is around 15-20% due to visceral inflammatory injuries and serious bacterial infections. The morbidity is also very important (92% at 1 year), especially ophthalmologic with high risk of blindness. There is currently no effective treatment.

Our team recently demonstrated that the severity of the disease correlates with the quantity and quality of CD8+ T lymphocytes which are activated in the active phase of disease. An activation marker has been identified, the CD38 receptor, which is very strongly expressed on the T clones responsible for the disease in the skin or blood of patients The CD38 receptor is the target of several commercial therapeutic antibodies, including DARATUMUMAB, which is currently used for the treatment of myeloma. DARATUMUMAB is a depleting antibody that eliminates cells strongly expressing this receptor.

The hypothesis is that a single intravenous infusion of DARATUMUMAB upon hospital admission of a patient with drug-induced NET would eliminate pathogenic T cells, thereby slowing disease progression, severity (% BSA with skin detachment, mortality rate) and sequelae.

02

Conditions studied

  • Toxic Epidermal Necrolysis
  • Immunotherapy
  • Cutaneous Adverse Drug Reactions (CADR)

Keywords

  • Toxic Epidermal Necrolysis (TEN)
  • Stevens-Johnson Syndrome (SJS)
  • anti-CD38+
  • DARATUMUMAB
  • Simon design
  • Lyell syndrome
03

In context

Stevens-Johnson Syndrome

40 studies on the registry are indexed under Stevens-Johnson Syndrome; 8 are open to participants now.

This study's planned enrollment of 9 is below the median of 20 across 24 interventional studies indexed under Stevens-Johnson Syndrome.

Browse Stevens-Johnson Syndrome studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 448 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult, over 18 years old, with drug-induced SJS/NET, proven or very strongly suspected (indirect argument of certainty) and confirmed by the evaluator.
  • SJS or NET or overlap syndrome evolving for less than 7 days prior to inclusion and with a progression of the detachment or rash observed within 48 hours prior to DARATUMUMAB treatment.
  • Negative screening (HBs, anti HBs and HBc).
  • The patient (or a trusted support person, family member, or close relative in case of emergency) must be capable of understanding the objectives of the trial and must have given free, informed, and express consent.
  • Patient affiliated to the Social Security system or benefiting from a similar system.
  • Negative beta HCG pregnancy test for women of and agreement to use effective during the study and up to 3 months after stopping DARATUMUMAB treatment.

Exclusion criteria

Exclusion Criteria:

  • Patient with Lyell syndrome induced by immunotherapy.
  • Known to the active substance (DARZALEX) or to one of the (L-histidine, L-histidine hydrochloride monohydrate, L-methionine, Polysorbate 20 Sorbitol -E420).
  • Patient with known hereditary fructose intolerance (HFI).
  • Patient with known history of (COPD).
  • Patient admitted with septic shock.
  • PMNs \< 1,500 /mm3 on CBC at inclusion visit.
  • Pregnant or breast-feeding women.
  • Patient under protective measures (safeguard, curatorship, guardianship) or deprived of liberty.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Experimental

    Single intravenous infusion of DARATUMUMAB 16 mg/kg body weight.

    Drug: DARATUMUMAB (DARZALEX®)

Interventions

  • A single injection of DARZALEX 16 mg/kg body weight administered by intravenous infusion (day 1) in addition to standard symptomatic treatment of NET until re-epidermalization.

06

What researchers measure

Primary outcomes

  1. From baseline up to 24 hours after end of infusion: tolerance criteria defined as occurence of infusion related reactions, Cytokine release syndrome, main hemostasis parameters or variation in main biological parameters (blood ionogram).

    Tolerance criteria according to NCI-CTCAE v5 criteria is defined as occurence of infusion related reactions; Cytokine release syndrome is characterized by increased levels of serum pro-inflammatory mediators; Main hemostasis parameters (prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FBG), thromobin time (TT), and D-dimer (DD); Variation in main biological parameters (blood ionogram).

    Time frame: At baseline and 24 hours after completion of the infusion of DARZALEX. If a clinical symptom or reaction is observed during infusion, an additional blood samples will be taken after a single intravenous infusion of DARZALEX 16 mg/kg body weight at day 1.

  2. Efficacy defined as stop of disease progression at Day 6

    The cessation of disease progression at day 6 (D6) will be assessed by evaluating the change in the percentage of body surface area with skin detachment (detached and/or bullous surfaces, and/or associated with Nikolsky's sign) between the baseline (before daratumumab administration) and day 6 (D6), according to the following rules : * ≤ 2% for Stevens-Johnson Syndrome, * ≤ 5% for overlap syndrome * ≤ 10% for Lyell syndrome And without any new lesion with skin detachment. The percentage of body surface area with skin detachment will be evaluated based on the stable burn table using the E-Burn® application Day 6 after an intravenous injection of darzalex (16mg/kg) in addition to the reference symptomatic treatment (Day 1 = infusion of darzalex treatment)

    Time frame: Day 6 after an intravenous injection of darzalex (16mg/kg)

  3. The occurrence of grade 3 or higher cardiovascular, renal, thyroid, or intestinal adverse events within two months of injection (seven times the nine-day half-life of daratumumab)

    Occurrence of grade \>=3 cardiovascular, renal, thyroid or intestinal adverse events, according to NCI-CTCAE v5 criteria.

    Time frame: Up to 2 months after the DARATUMUMAB infusion.

Secondary outcomes

  1. Measure time between index date (onset of first symptom) and initiation of DARATUMUMAB treatment (Day 1)

    Total number of days between the unique intravenous infusion of DARATUMUMAB at day 1 and onset of first symptoms leading to the diagnosis of TEN (Toxic Epidermal Necrolysis)

    Time frame: From date of onset of first symptoms leading to the diagnosis of TEN (Toxic Epidermal Necrolysis) until the unique infusion of DARATUMUMAB treatment at (Day 1)]

  2. Stop TEN progression delay: Time in days from start of DARATUMUMAB injection (Day 1) to cessation of progression

    Total number of days between intravenous infusion of DARATUMUMAB (day 1) and the documented stopping progression of TEN

    Time frame: From the date of DARATUMUMAB infusion (Day 1) until the documented date of stopping progression of TEN, assessed up to 12 months or date of death from any cause

  3. Complete re-epidermalization delay: Time in days from start of DARATUMUMAB infusion (Day 1) to complete re-epidermalization

    The complete re-epidermalization is defined as disappearance of skin erosions AND return to normal skin. The complete re-epidermalization is the total number of days between DARATUMUMAB injection (day 1) to complete re-epidermalization.

    Time frame: From the date of DARATUMUMAB infusion (day 1) until the documented date of complete re-epidermization, assessed up to 12 months or date of death from any cause.

  4. Hospital stay : measure the length of stay in one of the intensive care, burn, or internal medicine departments at Hôpital Édouard Herriot.

    Length of stay in E. Herriot hospital units care: Time between admission and discharge from E Herriot hospital

    Time frame: From admission to end of 12-month follow-up period

  5. Co-morbidities associated with the NET: document ophthalmological, gynecological, pulmonary, digestive, psychiatric, urological, stomatological/ORL, dermatological, hepatic, nephrological sequelae at 2, 6 and 12 months after Day1 (injection of Darzalex).

    Absence or presence of any co-morbitity: ophthalmological, gynecological, pulmonary, digestive, psychiatric, urological, stomatological/ORL, dermatological, hepatic and nephrological adverse event related to the disease and grade according to NCI-CTCAE v5 criteria.

    Time frame: At 2 months, 6 months and 12 months after Day 1 (injection of Daratumumab)

  6. Overall survival measure at Day 15 and 12 months after Darzalex infusion (D1)

    Overall survival rate defined as percentage of deaths

    Time frame: At Day15 and 12 months after Darzalex infusion (Day 1).

07

Study locations

1 site
  • Reference Center for Toxic, Toxin and Toxidermal Bullous Dermatoses - E. Herriot Hospital
    Lyon, 69437, France
    • Benoit BENSAID, Hospital practitioner · Contactbenoit.ben-said@chu-lyon.fr · +33 4 72 11 72 11
    • Florence HACARD, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Oct 2028, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2025
First posted
Aug 7, 2025
StartEst.
Oct 29, 2025
Primary completionEst.
Oct 29, 2028
CompletionEst.
Apr 29, 2029
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110662
Collaborators
Janssen-Cilag Ltd., INSERM U1111
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Oct 29, 2025 (estimated)
Primary completion
Oct 29, 2028 (estimated)
Completion
Apr 29, 2029 (estimated)
Last update
Aug 7, 2025

Study contacts

Benoit BENSAID, Hospital practitioner
Contact
benoit.ben-said@chu-lyon.fr
+33 4 72 11 72 11
Annie IUNG, Project Manager
Contact
annie.iung@chu-lyon.fr
+33 4 72 40 68 24

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion